FDA warning letters
This article was originally published in The Tan Sheet
Sixteen dietary supplement and hormone cream marketers have received warning letters for "making unproven claims that tout the benefits of their 'alternative hormone therapy' products in treating or preventing serious diseases including cancer, heart disease and osteoporosis," FDA announces Nov. 10. Unproven claims include "reversing osteoporosis-related bone loss and increasing bone density"; "reducing, arresting or inhibiting the growth of cancer cells" and "treating various forms of arthritis." Bio-Health, Greatest Herbs on Earth and Suzanne's Natural Foods were among the firms warned. In a joint effort, FTC notified 34 websites promoting "alternative hormone therapy" that their products lack "competent and reliable scientific evidence" to support their claims...
You may also be interested in...
More than half of the 34 Web site operators who received warning letters from the Federal Trade Commission regarding misleading claims for "natural" progesterone creams continue to sell the products with claims they are safe and can cure certain diseases, the commission reported in testimony to a Senate committee April 19
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.